Abstract
Spondyloarthritis (SpA) is a group of immune-mediated diseases highly concomitant with non-musculoskeletal inflammatory disorders such as acute anterior uveitis and Crohn’s disease. The gut microbiome represents a promising avenue to elucidate their underlying pathophysiology. Using discriminatory statistical methods to disentangle disease signals from one another and potential confounders, we characterized microbial signatures shared and distinct among these diseases for the first time, and established the baseline microbiota of a mixed prospective cohort. We identified a shared immune-mediated disease signal, represented by lower abundances of Lachnospiraceae taxa, most notably Blautia and Ruminococcus gauvreauii group. Patients with SpA were specifically enriched in Collinsella and Lactobacillus co-occurring with increased inflammation, while HLA-B27+ individuals displayed enriched Faecalibacterium. Our results indicate that the shared depletion of short-chain fatty acid producing Lachnospiraceae taxa may stem from different dysbiotic states previously described as enterotypes, which reflect long-term dietary and medication patterns and capture persistent, idiosyncratic variation between individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in part by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) as part of a clinical research unit (CRU339): Food allergy and tolerance (FOOD@), Project No. 428046232 and CRC-TRR241 and CRC1449 to B.S. T.S. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy, EXC 2155 "RESIST", Project ID 39087428. Additional funding was received from the German Federal Ministry for Health and Research (BMBF) as part of the WHEAT-A-BAIC consortium, and from the Berlin Institute of Health (BIH). The OptiRef control cohort was partially supported from an unrestricted research grant from Novartis, and the AAU cohort by a grant from AbbVie.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical committee of Charité-Universitätsmedizin Berlin gave ethical approval for this work, and all patients gave their written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors